Business
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Subsidiary HOPE Therapeutics to Acquire 49% Stake in Leading Florida Psychiatry Clinic
This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community. LOS ANGELES, CA - June 26, 2025 (NEWMEDIAWIRE) - NRx Pharmaceuticals (NASDAQ: NRXP), via its wholly owne...
About this update from Nrx Pharmaceuticals, Inc.
[{"type":"text","content":"This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community.","length":145,"tagName":"p"},{"type":"text","content":"LOS ANGELES, CA - June 26, 2025 (NEWMEDIAWIRE) - NRx Pharmaceuticals (NASDAQ: NRXP), via its wholly owned subsidiary HOPE Therapeutics(TM), Inc., has signed a binding Letter of Intent to acquire a 49% interest in Cohen and Associates, LLC, a top interventional psychiatry clinic founded by Dr. Rebecca Cohen in the Sarasota-Bradenton region. The clinic offers advanced treatments for suicidal depression, PTSD, and CNS disorders, including ketamine, Spravato, and TMS. The deal aims to establish a foundational clinic for HOPE's regional growth and reflects its mission to deliver compassionate, evidence-based mental health care. Final terms remain subject to closing and definitive agreements.","length":699,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":"Investor Brand Network","className":"","disableSlideshowImg":false,"size":{"original":{"width":1400,"height":800,"url":"https://media.zenfs.com/en/newsmediawire_165/176e8941c94808aff9c938d472630a9d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/f0t0bTfV_CQY6oMk1_54vg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0OTtjZj13ZWJw/https://media.zenfs.com/en/newsmediawire_165/176e8941c94808aff9c938d472630a9d","width":960,"height":549},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/i9X7sGC08kCH4Q5xzgPrJg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xMzcyO2NmPXdlYnA-/https://media.zenfs.com/en/newsmediawire_165/176e8941c94808aff9c938d472630a9d","width":1200,"height":686}}},{"type":"text","content":"To view the full press release, visit https://ibn.fm/0cNgG","length":58,"tagName":"p"},{"type":"text","content":"About NRx Pharmaceuticals, Inc.","length":31,"tagName":"p"},{"type":"text","content":"NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in p...